首页 | 本学科首页   官方微博 | 高级检索  
检索        

米氮平与氟西汀治疗抑郁症的多中心对照研究
引用本文:翁史,李华芳,赵靖平,张鸿燕,李婷,舒良,陈远光,马崔,顾牛范.米氮平与氟西汀治疗抑郁症的多中心对照研究[J].中国新药与临床杂志,2001,20(5):329-333.
作者姓名:翁史  李华芳  赵靖平  张鸿燕  李婷  舒良  陈远光  马崔  顾牛范
作者单位:1. 上海市精神卫生中心
2. 湖南医科大学精神卫生研究所,
3. 北京大学精神卫生研究所
4. 广东省广州市精神病医院
5. 北京大学精神卫生研究所,
摘    要:目的 :评价米氮平与氟西汀治疗抑郁症的有效性和安全性。方法 :采用DSM Ⅳ抑郁症的诊断标准 ,为期 6wk的观察。结果 :经 6wk治疗 ,米氮平组有效率和治愈率分别为 78%和 64% ,氟西汀组为 90 %和 55% (P >0 .0 5)。治疗 1wk后 ,米氮平组的有效率高于氟西汀组。 2组HAMD和MADRS总分治疗前后比较差异有显著意义 ,2组间差异无显著意义。治疗 1wk后 ,米氮平组HAMD总分和睡眠紊乱因子分的减分较氟西汀组明显。米氮平组主要不良反应是眩晕或 (和 )头昏等 ,与氟西汀组相比 ,米氮平组嗜睡发生率高 (P <0 .0 5)。结论 :米氮平是一种安全、有效的新型抗抑郁药物。起效较快 ,且有改善焦虑及睡眠作用

关 键 词:米氮平  氟西汀  抑郁症  多中心研究  药物评价
文章编号:1007-7669(2001)05-0329-05

Mirtazapine vs fluoxetine in treatment of major depressive disorder: a multicenter clinical trial
WENG Shi Min ,LI Hua Fang ,ZHAO Jing Ping ,ZHANG Hong Yan ,LI Ting ,SHU Liang ,CHEN Yuang Guang ,MA Cui ,GU Niu Fan.Mirtazapine vs fluoxetine in treatment of major depressive disorder: a multicenter clinical trial[J].Chinese Journal of New Drugs and Clinical Remedies,2001,20(5):329-333.
Authors:WENG Shi Min  LI Hua Fang  ZHAO Jing Ping  ZHANG Hong Yan  LI Ting  SHU Liang  CHEN Yuang Guang  MA Cui  GU Niu Fan
Institution:WENG Shi Min 1,LI Hua Fang 1,ZHAO Jing Ping 2,ZHANG Hong Yan 3,LI Ting 4,SHU Liang 3,CHEN Yuang Guang 2,MA Cui 4,GU Niu Fan 1
Abstract:AIM: To compare efficacy and safety of mirtazapine and fluoxetine in the treatment of major depressive disorder. METHODS: One hundred and thirty one patients were allocated by diagnosis of depressive disorder with DSM Ⅳ. Mirtazapine group (64 patients, age 39 a± s 13 a) and fluoxetine group (67 patients, age 36 a±11 a) were treated for 6 wk. Therapeutic effects were evaluated with Hamilton Rating for Depression Scale (HAMD), Montgomery Asberg Rating Scale (MADRS) and Clinical Global Impression (CGI). Safety were evaluated with Treatment Emergent Symptom Scale (TESS), physical and laboratory examination. RESULTS: After 6 wk treatment, the effective rate and cured rate of mirtazapine group and fluoxetine group were 78% and 64%; 90% and 55% respectively ( P >0.05). The effective rate of mirtazapine group was higher than that of fluoxetine group at wk 1 ( P <0.05). The scores of HAMD and MADRS in two groups were statistical difference before and after treatment ( P <0.01). There was no significant difference between two groups ( P >0.05). The decreased sub scores of HAMD in sleep disturbance in mirtazapine group were lower than that in fluoxetine group at wk 1 ( P <0.05). The main adverse reations of mirtazapine group were dizziness, drowsiness, mouth dry, weight gain, headache and agitation. The rate of drowsiness of mirtazapine group was higher compared with fluoxetine group( P < 0.05 ). Other adverse reactions were no obvious difference between two groups. CONCLUSION: Mirtazapine is an effective, well tolerated and rapidly responded new antidepressant. Moreover, this durg is effective in the treatment of sleep disorder and anxiety.
Keywords:mirtazapine  fluoxetine  depression  multicentre studies  drug evaluation
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号